Lycera Stock

lycera.comBioTechFounded: 1900Funding to Date: $106.06MM

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer.

Register for Details

For more details on financing and valuation for Lycera, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Alex Howarth
Chief Financial Officer
Bruce Goldsmith Ph.D
Chief Operating Officer and Chief Business Officer
H. Jeffrey Wilkins MD
Chief Medical Officer
William Sibold
Co-Chief Executive Officer & President
Paul Sekhri
President, Co-Chief Executive Officer & Board Member

Board Members

Finny Kuruvilla Ph.D
Blackstone Life Sciences
Jeffrey Leiden Ph.D
Blackstone Life Sciences
Kristina Burow
ARCH Venture Partners
Mary Campbell
EDF Ventures
Michael Hayden Ph.D
Nicholas Simon
Blackstone Life Sciences
Nina Kjellson
InterWest Partners
Pablo Cagnoni MD
Paul Sekhri
Robert Kamen Ph.D
Steven Gillis Ph.D
ARCH Venture Partners
Timothy Mayleben

Other companies like Lycera in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM